Vanda Pharmaceuticals (VNDA) is up 40.1% today. Here is some analysis on what might have caused this price movement.
Analysis: VNDA appears to be rallying after Vanda announced U.S. FDA approval of BYSANTI (milsaperidone), a new antipsychotic for bipolar I disorder (manic or mixed episodes) and schizophrenia. The approval expands Vanda’s psychiatry franchise and introduces a second newly approved product in a short period, which investors may be pricing as a meaningful incremental revenue opportunity.
Details:
Sources:
PR Newswire, Drugs.com, Nasdaq
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$VNDA Hedge Fund Activity
We have seen 66 institutional investors add shares of $VNDA stock to their portfolio, and 97 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TANG CAPITAL MANAGEMENT LLC removed 2,353,307 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $20,756,167
- AIGH CAPITAL MANAGEMENT LLC added 1,998,431 shares (+inf%) to their portfolio in Q4 2025, for an estimated $17,626,161
- MILLENNIUM MANAGEMENT LLC removed 1,571,823 shares (-48.4%) from their portfolio in Q4 2025, for an estimated $13,863,478
- BLACKROCK, INC. removed 1,144,770 shares (-12.8%) from their portfolio in Q4 2025, for an estimated $10,096,871
- JACOBS LEVY EQUITY MANAGEMENT, INC added 599,818 shares (+552.3%) to their portfolio in Q4 2025, for an estimated $5,290,394
- MARSHALL WACE, LLP removed 581,247 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,126,598
- PRUDENTIAL FINANCIAL INC removed 449,403 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,963,734
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$VNDA Government Contracts
We have seen $171,234 of award payments to $VNDA over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PHARM - HETLIOZ: $171,234
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
$VNDA Analyst Ratings
Wall Street analysts have issued reports on $VNDA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 02/23/2026
- Cantor Fitzgerald issued a "Overweight" rating on 10/30/2025
To track analyst ratings and price targets for $VNDA, check out Quiver Quantitative's $VNDA forecast page.
$VNDA Price Targets
Multiple analysts have issued price targets for $VNDA recently. We have seen 4 analysts offer price targets for $VNDA in the last 6 months, with a median target of $12.5.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $24.0 on 02/23/2026
- Chris Howerton from Jefferies set a target price of $7.5 on 12/31/2025
- Madison El-Saadi from B. Riley Securities set a target price of $14.0 on 12/31/2025
- Olivia Brayer from Cantor Fitzgerald set a target price of $11.0 on 10/30/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
